ArticleAntimicrobial agents and chemotherapy2016
Derivation and Multicenter Validation of the Drug Resistance in Pneumonia Clinical Prediction Score.
Article in Antimicrobial agents and chemotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 3 syntheses or guidelines pooled it, 76 citations in OpenAlex.
- Efficacy and safety of traditional Chinese medicine injections for older adults with community-acquired pneumonia: An evidence map.Medicine · 2025Pooled it
- Risk factors for drug-resistant pathogens in community-acquired pneumonia: systematic review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2025Pooled it
- Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America.American journal of respiratory and critical care medicine · 2019Guideline
- RESPIRE Score: Derivation and Validation of a New Risk Score for Prediction of Community-acquired Pneumonia Caused by Resistant Pathogens.Open forum infectious diseases · 2026Article
- Personalised management of community-acquired pneumonia and the role of Clinical Decision Support Software.BMJ open respiratory research · 2026Review
- Aerobic bacteria study, clinical spectrum, and outcome of patients with community-acquired multidrug-resistant pathogens.Journal of family medicine and primary care · 2024Article
- Methicillin-resistantJournal of the American College of Emergency Physicians open · 2023Article
- Ten Issues to Update in Nosocomial or Hospital-Acquired Pneumonia: An Expert Review.Journal of clinical medicine · 2023Review
- Derivation and validation of a risk assessment model for drug-resistant pathogens in hospitalized patients with community-acquired pneumonia.Infection control and hospital epidemiology · 2023Article
- ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia.Intensive care medicine · 2023Article
- Identify Drug-Resistant Pathogens in Patients with Community-Acquired Pneumonia.Advances in respiratory medicine · 2023Review
- Machine Learning To Stratify Methicillin-Resistant Staphylococcus aureus Risk among Hospitalized Patients with Community-Acquired Pneumonia.Antimicrobial agents and chemotherapy · 2023Article
- Severe community-acquired pneumonia.European respiratory review : an official journal of the European Respiratory Society · 2022Review
- How and when to manage respiratory infections out of hospital.European respiratory review : an official journal of the European Respiratory Society · 2022Review
- Derivation and Validation of a Clinical Prediction Score to Identify the Isolation of Pseudomonas in Pneumonia.Microbiology spectrum · 2022Article
- Empiric Treatment in HAP/VAP: "Don't You Want to Take a Leap of Faith?"Antibiotics (Basel, Switzerland) · 2022Review
- It's about the patients: Practical antibiotic stewardship in outpatient settings in the United States.Frontiers in medicine · 2022Review
- Deploying an Electronic Clinical Decision Support Tool for Diagnosis and Treatment of Pneumonia Into Rural and Critical Access Hospitals: Utilization, Effect on Processes of Care, and Clinician Satisfaction.The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association · 2022Article
- Diagnosis of Multidrug-Resistant Pathogens of Pneumonia.Diagnostics (Basel, Switzerland) · 2021Review
- Advances in novel antibiotics to treat multidrug-resistant gram-negative bacterial infections.Internal and emergency medicine · 2021Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
12 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The health care-associated pneumonia (HCAP) criteria have a limited ability to predict pneumonia caused by drug-resistant bacteria and favor the overutilization of broad-spectrum antibiotics. We aimed to derive and validate a clinical prediction score with an improved ability to predict the risk of pneumonia due to drug-resistant pathogens compared to that of HCAP criteria. A derivation cohort of 200 microbiologically confirmed pneumonia cases in 2011 and 2012 was identified retrospectively. Risk factors for pneumonia due to drug-resistant pathogens were evaluated by logistic regression, and a novel prediction score (the drug resistance in pneumonia [DRIP] score) was derived. The score was then validated in a prospective, observational cohort of 200 microbiologically confirmed cases of pneumonia at four U.S. centers in 2013 and 2014. The DRIP score (area under the receiver operator curve [AUROC], 0.88 [95% confidence interval {CI}, 0.82 to 0.93]) performed significantly better (P = 0.02) than the HCAP criteria (AUROC, 0.72 [95% CI, 0.64 to 0.79]). At a threshold of ≥4 points, the DRIP score demonstrated a sensitivity of 0.82 (95% CI, 0.67 to 0.88), a specificity of 0.81 (95% CI, 0.73 to 0.87), a positive predictive value (PPV) of 0.68 (95% CI, 0.56 to 0.78), and a negative predictive value (NPV) of 0.90 (95% CI, 0.81 to 0.93). By comparison, the performance of HCAP criteria was less favorable: sensitivity was 0.79 (95% CI, 0.67 to 0.88), specificity was 0.65 (95% CI, 0.56 to 0.73), PPV was 0.53 (95% CI, 0.42 to 0.63), and NPV was 0.86 (95% CI, 0.77 to 0.92). The overall accuracy of the HCAP criteria was 69.5% (95% CI, 62.5 to 75.7%), whereas that of the DRIP score was 81.5% (95% CI, 74.2 to 85.6%) (P = 0.005). Unnecessary extended-spectrum antibiotics were recommended 46% less frequently by applying the DRIP score (25/200, 12.5%) than by use of HCAP criteria (47/200, 23.5%) (P = 0.004), without increasing the rate at which inadequate treatment recommendations were made. The DRIP score was more predictive of the risk of pneumonia due to drug-resistant pathogens than HCAP criteria and may have the potential to decrease antibiotic overutilization in patients with pneumonia. Validation in larger cohorts of patients with pneumonia due to all causes is necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.